PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. 1991 April; 87(4): 1462–1466.
PMCID: PMC295198

CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual.

Abstract

The extent of antiviral activity exhibited in vitro by CD8+lymphocytes from individuals infected by HIV-1 correlates significantly with their clinical status. CD8+ lymphocytes from asymptomatic subjects were found to inhibit HIV-1 replication by 90% or greater at effector/target (E/T) ratios ranging from as low as 0.05 to 0.25. CD8+ cells from 17 of 19 (89%) of these subjects suppressed replication at an E/T ratio of 0.10 or less. CD8+ lymphocytes from symptomatic patients (non-AIDS) inhibited HIV-1 replication at E/T ratios ranging from 0.05 to 1.0, and CD8+ cells from 8 of 13 (62%) required ratios greater than 0.10. As a group, patients with AIDS exhibited the lowest degree of anti-HIV activity with their CD8+ lymphocytes. The effective range of E/T ratios from AIDS patients was 0.10-2.0, and 9 of 10 (90%) required E/T ratios greater than 0.25. This anti-HIV activity exhibited by CD8+ cells also correlated significantly with the subject's peripheral blood CD4+ cell count. The relative extent of CD8+ cell anti-HIV-1 activity was not found dependent on variations in the CD4+ target cells and viruses used. These findings suggest that the decreased CD8+ cell antiviral activity is related to progression to disease in HIV-infected individuals.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1016K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Yap KL, Ada GL, McKenzie IF. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature. 1978 May 18;273(5659):238–239. [PubMed]
  • Leclerc JC, Cantor H. T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo. J Immunol. 1980 Feb;124(2):851–854. [PubMed]
  • Engers HD, Lahaye T, Sorenson GD, Glasebrook AL, Horvath C, Brunner KT. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones. J Immunol. 1984 Sep;133(3):1664–1670. [PubMed]
  • Quinnan GV, Jr, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, Santos GW, Saral R, Burns WH. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med. 1982 Jul 1;307(1):7–13. [PubMed]
  • McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med. 1983 Jul 7;309(1):13–17. [PubMed]
  • Ojo-Amaize EA, Nishanian P, Keith DE, Jr, Houghton RL, Heitjan DF, Fahey JL, Giorgi JV. Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus-infected cells. J Immunol. 1987 Oct 1;139(7):2458–2463. [PubMed]
  • Shepp DH, Chakrabarti S, Moss B, Quinnan GV., Jr Antibody-dependent cellular cytotoxicity specific for the envelope antigens of human immunodeficiency virus. J Infect Dis. 1988 Jun;157(6):1260–1264. [PubMed]
  • Evans LA, Thomson-Honnebier G, Steimer K, Paoletti E, Perkus ME, Hollander H, Levy JA. Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV. AIDS. 1989 May;3(5):273–276. [PubMed]
  • Creemers PC, Stark DF, Boyko WJ. Evaluation of natural killer cell activity in patients with persistent generalized lymphadenopathy and acquired immunodeficiency syndrome. Clin Immunol Immunopathol. 1985 Aug;36(2):141–150. [PubMed]
  • Bonavida B, Katz J, Gottlieb M. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2. J Immunol. 1986 Aug 15;137(4):1157–1163. [PubMed]
  • Plata F, Autran B, Martins LP, Wain-Hobson S, Raphaël M, Mayaud C, Denis M, Guillon JM, Debré P. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature. 1987 Jul 23;328(6128):348–351. [PubMed]
  • Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, Durno AG, Blumberg RS, Kaplan JC, Hirsch MS, Schooley RT. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987 Jul 23;328(6128):345–348. [PubMed]
  • Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature. 1988 Dec 1;336(6198):484–487. [PubMed]
  • Hoffenbach A, Langlade-Demoyen P, Dadaglio G, Vilmer E, Michel F, Mayaud C, Autran B, Plata F. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol. 1989 Jan 15;142(2):452–462. [PubMed]
  • Guillon JM, Autran B, Denis M, Fouret P, Plata F, Mayaud CM, Akoun GM. Human immunodeficiency virus-related lymphocytic alveolitis. Chest. 1988 Dec;94(6):1264–1270. [PubMed]
  • Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986 Dec 19;234(4783):1563–1566. [PubMed]
  • Kannagi M, Chalifoux LV, Lord CI, Letvin NL. Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes. J Immunol. 1988 Apr 1;140(7):2237–2242. [PubMed]
  • Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ T lymphocyte control of HIV replication in cultured CD4+ cells varies among infected individuals. Cell Immunol. 1989 Apr 1;119(2):470–475. [PubMed]
  • Brinchmann JE, Gaudernack G, Vartdal F. CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. J Immunol. 1990 Apr 15;144(8):2961–2966. [PubMed]
  • Wiviott LD, Walker CM, Levy JA. CD8+ lymphocytes suppress HIV production by autologous CD4+ cells without eliminating the infected cells from culture. Cell Immunol. 1990 Jul;128(2):628–634. [PubMed]
  • Walker CM, Levy JA. A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology. 1989 Apr;66(4):628–630. [PubMed]
  • Levy JA, Shimabukuro J. Recovery of AIDS-associated retroviruses from patients with AIDS or AIDS-related conditions and from clinically healthy individuals. J Infect Dis. 1985 Oct;152(4):734–738. [PubMed]
  • Levy JA, Tobler LH, McHugh TM, Casavant CH, Stites DP. Long-term cultivation of T-cell subsets from patients with acquired immune deficiency syndrome. Clin Immunol Immunopathol. 1985 Jun;35(3):328–336. [PubMed]
  • Hoffman AD, Banapour B, Levy JA. Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology. 1985 Dec;147(2):326–335. [PubMed]
  • Kaminsky LS, McHugh T, Stites D, Volberding P, Henle G, Henle W, Levy JA. High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci U S A. 1985 Aug;82(16):5535–5539. [PubMed]
  • Lang W, Perkins H, Anderson RE, Royce R, Jewell N, Winkelstein W., Jr Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr. 1989;2(1):63–69. [PubMed]
  • Cheng-Mayer C, Seto D, Tateno M, Levy JA. Biologic features of HIV-1 that correlate with virulence in the host. Science. 1988 Apr 1;240(4848):80–82. [PubMed]
  • Giorgi JV, Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol. 1989 Jul;52(1):10–18. [PubMed]
  • Rosenberg ZF, Fauci AS. The immunopathogenesis of HIV infection. Adv Immunol. 1989;47:377–431. [PubMed]
  • Gluckman JC, Klatzmann D, Cavaille-Coll M, Brisson E, Messiah A, Lachiver D, Rozenbaum W. Is there correlation of T cell proliferative functions and surface marker phenotypes in patients with acquired immune deficiency syndrome or lymphadenopathy syndrome? Clin Exp Immunol. 1985 Apr;60(1):8–16. [PubMed]
  • Gurley RJ, Ikeuchi K, Byrn RA, Anderson K, Groopman JE. CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci U S A. 1989 Mar;86(6):1993–1997. [PubMed]
  • Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989 Dec 14;321(24):1621–1625. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation